A Meta-Analysis of Genome-Wide Association Scans Identifies IL18RAP, PTPN2, TAGAP, and PUS10 As Shared Risk Loci for Crohn’s Disease and Celiac Disease

Eleonora A. M. Festen1,2, Philippe Goyette3, Todd Green4, Gabrielle Boucher3, Claudine Beauchamp3, Gosia Trynka2, Patrick C. Dubois5, Caroline Lagacé3, Pieter C. F. Stokkers6, Daan W. Hommes7, Donatella Barisani8, Orazio Palmieri9, Vito Annese9, David A. van Heel5, Rinse K. Weersma1, Cisca Wijmenga2, John D. Rioux3,*, Mark J. Daly4,10,*, Michel Georges, University of Liège, Belgium

1 Department of Gastroenterology and Hepatology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands, 2 Department of Genetics, University Medical Centre Groningen and University of Groningen, Groningen, The Netherlands, 3 Research Center, Université de Montréal and the Montreal Heart Institute, Montreal, Quebec, Canada, 4 The Broad Institute, Cambridge, Massachusetts, United States of America, 5 Centre for Digestive Diseases, Blizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 6 Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands, 7 Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands, 8 Department of Experimental Medicine, Faculty of Medicine, University of Milano-Bicocca, Monza, Italy, 9 U. O. Gastroenterologia ed Endoscopia Digestiva, Ospedale “Casa Sollievo della Sofferenza”, IRCCS, San Giovanni Rotondo, Italy, 10 Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

Abstract

Crohn’s disease (CD) and celiac disease (CeID) are chronic intestinal inflammatory diseases, involving genetic and environmental factors in their pathogenesis. The two diseases can co-occur within families, and studies suggest that CeID patients have a higher risk to develop CD than the general population. These observations suggest that CD and CeID may share common genetic risk loci. Two such shared loci, IL18RAP and PTPN2, have already been identified independently in these two diseases. The aim of our study was to explicitly identify shared risk loci for these diseases by combining results from genome-wide association study (GWAS) datasets of CD and CeID. Specifically, GWAS results from CeID (768 cases, 1,422 controls) and CD (3,230 cases, 4,829 controls) were combined in a meta-analysis. Nine independent regions had nominal association p-value <1.0×10^{-5} in this meta-analysis and showed evidence of association to the individual diseases in the original scans (p-value <1.0×10^{-2} in CeID and <1×10^{-3} in CD). These include the two previously reported shared loci, IL18RAP and PTPN2, with p-values of 3.37×10^{-11} and 6.39×10^{-9}, respectively, in the meta-analysis. The other seven had not been reported as shared loci and thus were tested in additional CeID (3,149 cases and 4,714 controls) and CD (1,835 cases and 1,669 controls) cohorts. Two of these loci, TAGAP and PUS10, showed significant evidence of replication (Bonferroni corrected p-values: <0.0071) in the combined CeID and CD replication cohorts and were firmly established as shared risk loci of genome-wide significance, with overall combined p-values of 1.55×10^{-10} and 1.38×10^{-11}, respectively. Through a meta-analysis of GWAS data from CD and CeID, we have identified four shared risk loci: PTPN2, IL18RAP, TAGAP, and PUS10. The combined analysis of the two datasets provided the power, lacking in the individual GWAS for single diseases, to detect shared loci with a relatively small effect.


Editor: Michel Georges, University of Liège, Belgium

Received March 10, 2010; Accepted December 20, 2010; Published January 27, 2011

Copyright: © 2011 Festen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The study was supported by the Celiac Disease Consortium, an Innovative Cluster approved by the Netherlands Genomics Initiative and partially funded by the Dutch Government (80803009); by the Netherlands Organization for Scientific Research (NWO, VICI grant 918.66.620 to CW, AGIKO grant 92.003.533 to EAMF, KF grant 907.00.281 to RKW); by the National Institutes of Allergy and Infectious Diseases (grant AI065687, AI067152 to JDR); by the National Institutes of Health (grant DK064869, DK062432 to JDR); by the Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America; and by the Wellcome Trust under award 085475. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: R.K.Weersma@int.umcg.nl (RKW); john.david.rioux@umontreal.ca (JDR)

† These authors contributed equally to this work.

‡ These authors also contributed equally to this work.
**Introduction**

Crohn’s disease (CD) and celiac disease (CelD) are both chronic intestinal inflammatory diseases. In CD inflammation can occur throughout the gastrointestinal tract but most commonly affects the ileal part of the small intestine. While the causative antigen(s) for this inflammation is unknown, it is thought that the disease arises as a reaction to the normal commensal flora of the bowel in a genetically susceptible individual [1,2]. In CelD inflammation is limited to the small intestine. CelD is caused by a reaction to gluten, a dietary peptide present in wheat, barley and rye [3,4]. In both CelD and CD contact between antigens and antigen-presenting cells (APCs) seems to be facilitated by an initial increase in intestinal permeability [5]. In both diseases the subsequent inflammatory response follows a T helper 1 pattern characterized by tumor necrosis factor beta (TNF-β) and interferon gamma (IFN-γ) production and a T helper 17 response marked by the production of interleukin 17 [5].

Although uncommon, it has been observed that CelD and CD can co-occur within families or even within individual patients; there appears to be a greater prevalence of CD among CelD patients than in the general population, although the relatively low prevalence of CD makes it difficult to establish this effect [6]. It is now well accepted that the risk for CD and CelD is partly determined by genetic factors, and recently many genetic risk factors for CelD and CD have been identified. Two genetic risk loci were previously shown to be shared between CelD and CD: a locus on 18p11 containing the PTPN2 (protein tyrosine phosphatase, non-receptor type 2) gene and a locus on 2q12 containing the IL18RAP (interleukin 18 receptor accessory protein) gene [7–13]. While these observations confirm the existence of shared risk loci for CD and CelD, additional such shared risk loci are likely to exist.

There are two possible approaches for identifying shared risk loci. One approach is to test known risk loci from one disease in patient-control cohorts from the other disease. This approach has already been successfully applied in a cross study between CelD and type 1 diabetes (T1D), where four shared risk loci were identified some of which were previously unknown to be associated to CelD [11]. However, this approach relies on previously identified risk alleles, indicating that there probably are many more unknown common risk loci for T1D and CelD. In addition, some of the shared loci will not have a large enough effect in the individual diseases to have been identified by previous genetic studies. A second approach that tackles this problem is to analyze genetic data from two similar diseases as a single unified disease phenotype against healthy controls. Such analysis would be expected to dilute disease-specific genetic associations, but increase the power for finding shared genetic risk loci of small effect in the individual diseases. The availability of genome-wide association studies (GWAS) performed in both CelD and CD provides large case-control genotyping datasets that enabled us to perform a cross-disease genome-wide meta-analysis in the aim of identifying novel shared risk loci.

To identify novel shared risk loci between CelD and CD, we performed a meta-analysis of two recently published GWAS: a large meta-analysis of three CD GWAS by the International IBD Genetics Consortium and a CelD GWAS in a British population. To confirm identified risk loci, we used a combination of Italian and Dutch CD cohorts and of British, Italian and Dutch CelD cohorts.

**Results**

**Meta-analysis**

We have performed a meta-analysis of 471,504 SNPs from genome-wide datasets of CD (3230 cases, 4829 controls) and CelD (768 cases, 1422 controls) in order to identify shared risk loci between the 2 diseases.

A quantile-quantile (Q-Q) plot of the association p-values for single-SNP Z scores from the meta-analysis was performed (Figure S1) and shows an excess of significant associations above what would be expected by chance. We observe a low inflation factor of 1.08, which is expected given the inflation observed in each of the original studies: 1.05 for CelD and 1.16 for CD. A Manhattan plot of the current study (Figure S2) highlights many strong association signals, several of which corresponding to previously reported CD and CelD loci; however, most of these show strong association in only one of the 2 diseases and have thus not been followed up due to the design of the current study. In addition, given the design of the original CelD GWAS, which included only individuals that were positive for the risk-associated allele HLA-DQ2, association to the major histocompatibility complex (MHC) region in CelD was of no relevance since it was artificially inflated. Therefore the MHC region (Chr6:22700000..35000000 from the NCBI B36 genome build) was removed from our analysis.

The meta-analysis of the CD and CelD datasets identified 25 SNPs, from 10 independent regions, that met our criteria for association (association with CelD at p-value <1×10^{-2} and with CD at p-value <1×10^{-3} in the original scans, as well as a nominal association p-value more significant than 1.0×10^{-3} in the meta-analysis) (Table 1 and Table S2). This is more than expected by chance, as we would expect no more than 3 independent regions to meet our criteria, which encouraged us to explore these specific loci further.

The strongest association signal identified in our scan was to the well accepted CD associated risk locus CARD15 (p-values of 3.42×10^{-52}, 3.77×10^{-53} and 1.30×10^{-21} in the CD, CelD and scan datasets respectively). Given the strength and the width of the association signal peak at this locus in the CD dataset, our chances of detecting a false positive shared signal at this locus in the scan were artificially increased. Because of this, the CARD15 locus was
Table 1. Results from the meta-analysis, replication, and combined analysis.

<table>
<thead>
<tr>
<th>Locus</th>
<th>SNP</th>
<th>Risk Allele</th>
<th>CD</th>
<th>Celiac Disease</th>
<th>CeD</th>
<th>meta-analysis</th>
<th>Replication</th>
<th>Combined Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>p-value</td>
<td>p-value</td>
<td>OR**</td>
<td>p-value</td>
<td>p-value</td>
<td>OR**</td>
</tr>
<tr>
<td>IL18RAP*</td>
<td>rs6708413</td>
<td>G</td>
<td>6.50×10⁻⁵</td>
<td>2.05×10⁻⁵</td>
<td>8.37×10⁻⁸</td>
<td>N.T.</td>
<td>N.T.</td>
<td>N.T.</td>
</tr>
<tr>
<td>PTPN2</td>
<td>rs16939895</td>
<td>C</td>
<td>2.06×10⁻³</td>
<td>4.62×10⁻⁹</td>
<td>6.39×10⁻⁹</td>
<td>N.T.</td>
<td>N.T.</td>
<td>N.T.</td>
</tr>
<tr>
<td>PUS10</td>
<td>rs10188217</td>
<td>C</td>
<td>8.30×10⁻³</td>
<td>6.14×10⁻⁶</td>
<td>3.33×10⁻⁶</td>
<td>1.14</td>
<td>4.52×10⁻⁵</td>
<td>1.16</td>
</tr>
<tr>
<td>CCDC91</td>
<td>rs10771427</td>
<td>G</td>
<td>2.09×10⁻³</td>
<td>5.72×10⁻⁵</td>
<td>4.00×10⁻⁶</td>
<td>1.00</td>
<td>0.94</td>
<td>1.02</td>
</tr>
<tr>
<td>3q13</td>
<td>rs1517605</td>
<td>T</td>
<td>5.60×10⁻⁴</td>
<td>1.98×10⁻⁸</td>
<td>3.22×10⁻⁶</td>
<td>1.02</td>
<td>0.67</td>
<td>0.98</td>
</tr>
<tr>
<td>TAGAP</td>
<td>rs212388</td>
<td>C</td>
<td>1.22×10⁻⁴</td>
<td>1.23×10⁻⁵</td>
<td>7.86×10⁻⁷</td>
<td>1.14</td>
<td>8.88×10⁻⁵</td>
<td>1.10</td>
</tr>
<tr>
<td>KCNG4</td>
<td>rs402544</td>
<td>A</td>
<td>5.69×10⁻⁵</td>
<td>2.97×10⁻⁵</td>
<td>6.58×10⁻⁶</td>
<td>0.96</td>
<td>0.19</td>
<td>1.00</td>
</tr>
<tr>
<td>C10orf72</td>
<td>rs4317904 #</td>
<td>A</td>
<td>2.09×10⁻⁴</td>
<td>2.80×10⁻⁴</td>
<td>1.87×10⁻⁶</td>
<td>1.04</td>
<td>0.26</td>
<td>1.06</td>
</tr>
<tr>
<td>FERMT1</td>
<td>rs6516104 #</td>
<td>T</td>
<td>5.87×10⁻⁵</td>
<td>6.19×10⁻⁴</td>
<td>1.36×10⁻⁶</td>
<td>1.04</td>
<td>0.47</td>
<td>0.97</td>
</tr>
</tbody>
</table>

The meta-analysis was performed using a directional non-weighed Z-score method as explained in the methods section. Combined analyses were performed using a directional weighted Z-score method within diseases and a directional non-weighed Z-score method between diseases. Results for the combined analysis are given only for the SNPs that pass the replication thresholds (directionality in each disease and p-value <0.001 for the combined replication data).

*, IL18RAP and PTPN2 were not followed up because they are known shared risk loci for CD and CeD; **, OR for the replication is reported for the allele identified as the risk allele in the initial scan; N.T., not tested. CeD = Celiac disease, CD = Crohn's disease, SNP = single nucleotide polymorphism, IL18RAP = interleukin 18 receptor accessory protein, PTPN2 = protein tyrosine phosphatase, PUS10 = pseudouridylate synthase 10, KCNG4 = potassium voltage-gated channel, subfamily G, member 4, non-receptor type 2, C10orf72 = Chromosome 10 open reading frame 72, FERMT1 = fermitin family homolog 1, 3q13, 9q13, 17p13 = intergenic regions.

doi:10.1371/journal.pgen.1001283.t001

Discussion

By performing a meta-analysis of GWAS data from CD and CeD as a single disease phenotype, we have identified four risk loci shared by these 2 diseases: PTPN2, IL18RAP, TAGAP and PUS10. This meta-analysis approach provided the power, lacking in individual disease-specific GWAS datasets, to identify shared risk loci with small effects in each single disease. This approach is a powerful and versatile way of identifying shared risk loci. In fact, two of the shared loci described here, TAGAP and PUS10, would not have reached genome-wide significance without the power gained from the combined samples (scan and replication) of these 2 diseases. As the GWAS for the individual diseases increase in power, we can expect the power of the current approach to also increase enabling us to identify further shared loci.

The TAGAP locus identified in the current study as a shared risk factor for CD and CeD is located on chromosome 6q25.3, within a 200-kb block of linkage disequilibrium (LD). This TAGAP locus was previously identified as a CeD risk locus [9] but not found in previous studies of CD. TAGAP is the best candidate of four genes in this region of strong LD [9]. TAGAP is a member of the Rho-GTPase protein family, which release GTP from GTP-bound Rho, thereby acting as a molecular switch. The gene is expressed in activated T cells and appears to be important for modulating cytokines changes [14]. Little is known about the shared loci assessed in previous studies of CeD.

not moved forward to replication. An evaluation of the association signal in the in silico CeD GWAS replication datasets confirmed that this locus did not show replication in CeD. Several of the SNPs mitting our criteria for association mapped to the known shared risk loci IL18RAP and PTPN2. Identifying these shared risk loci in the initial phase of our analysis provides proof of the effectiveness of our method. Interestingly, these two loci either reach or are very near genome-wide significance in the current meta-analysis (p-value of 8.37×10⁻⁸ for IL18RAP and of 6.39×10⁻⁹ for PTPN2), validating their previously identified role in both CD and CeD. The remaining 12 SNPs were located in seven independent regions and for each of these loci we selected the most associated SNP for testing for evidence of replication.

Replication phase

All SNPs selected for follow-up were genotyped in additional replication cohorts of CeD patients (n = 3149) and healthy controls (n = 4714) and of CD patients (n = 1941) and healthy controls (n = 1669). Given that these putative shared risk loci were selected through the combined analysis of our CD and CeD scan cohorts, a positive threshold for replication was therefore set at a corrected p-value of 0.0071 (Bonferroni corrected p-value of 0.05 for 7 independent tests) in the combined analysis of CD and CeD replication cohorts.

Only two of the 7 loci tested, PUS10 (pseudouridylate synthase 10; RefSeq NM_144709.2) and TAGAP (T-cell activation GTPase activating protein; RefSeq NM_054114), showed significant replication (p-values of 6.03×10⁻⁷ and 3.03×10⁻⁶ respectively) with matching direction of association between the scan and replication datasets, as well as replication p-values more significant than 0.05 in both CD and CeD replication cohorts independently (Table 1). While neither PUS10 nor TAGAP were identified as loci of genome-wide significance in the combined dataset from each disease (p-values = 1.34×10⁻⁸ and 7.00×10⁻⁷ in CeD and p-values = 6.16×10⁻⁸ and 2.13×10⁻⁶ in CD respectively), both reach genome-wide significance in a combined analysis of CD and CeD cohorts (p-values of 1.38×10⁻¹¹ and 1.55×10⁻¹⁰ respectively). Based on the results calculated from the replication datasets, we also observe that the effects at these 2 loci are similar in size and direction for both CD and CeD (Table 1).
exact role of \textit{TAGAP} in immune function, but it has been found to be co-regulated with \textit{IL2} and is expected to play a role in T-cell activation [14].

The current study also identifies a shared risk locus between CD and CeD in the \textit{PUS10} gene region, a locus previously described as a risk locus for CD [15]. This locus was recently identified as a risk locus for both ulcerative colitis (UC) and CeD, indicating that this locus may be a shared risk locus for these three diseases [7,16]. This latter finding further validates the approach used in this study to identify risk factors that are shared across diseases. Interestingly, the UC study identified three independent signals in this region which seem to be shared differently across these three diseases: one signal seems to be shared only between CD and UC, a second only between CeD and UC, while the third, identified in the current study, seems shared between all three diseases. Further analysis of this locus will be necessary in order to clarify the role of these different alleles in disease risk.

In this study we aimed to find shared genetic risk factors for CeD and CD by meta-analysis of GWAS data of both diseases, defining a single phenotype for these analyses. Using readily available data, we were able to reliably establish four shared loci: \textit{PTPN2}, \textit{IL1R1AP}, \textit{TAGAP} and \textit{PUS10}. For many diseases with overlapping phenotypic characteristics, GWAS data is available and joint analysis of GWAS datasets of these related diseases could lead to the identification of many new shared susceptibility loci.

**Materials and Methods**

**Subjects**

For the CD aspect of the meta-analysis, we used the previously published data (available at http://www.broadinstitute.org/~jcbarret/ibd-meta/) from the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC) meta-analysis of 3230 CD cases and 4829 healthy controls taken from three independent CD GWAS (Table S1) [15]. A more in depth description of these cohorts and their origin can be obtained from the original publication of this meta-analysis.

Two independent cohorts were used for the CD replication phase (Table S1). The first consisted of 1217 Dutch CD cases from three Dutch university medical centers: the Academic Medical Centre Amsterdam (n = 661), the University Medical Centre Groningen (n = 322) and the University Medical Centre Leiden (n = 234); the 804 Dutch controls used for this replication cohort were obtained from cohorts of healthy partners of IBD patients (n = 234); the 804 Dutch controls used for this replication cohort were obtained from all participants. Some controls were shared between the WTCCC component of the CD meta-analysis and the two UK CeD cohorts (one used in the original scan and one used as replication). This was taken into account as explained in the meta-analysis description.

**Imputation of GWAS data**

Imputation of the CeD datasets used in the initial and the replication phases of this study were performed with BEAGLE using HapMap phase II and HapMap phase III as reference datasets [21]. A minimum quality score for statistical certainty of the imputation of 0.98 was adhered to.

Imputation of the CD dataset for the initial CD-CeD meta-analysis was performed with the programs MACH and IMPUTE, using HapMap phase II as a reference dataset, as previously described [15,22,23].

**Meta-analysis**

For the original CD dataset, association tests were described previously [15]. Briefly, results for each SNP from three independent GWAS were summarized as Z-scores and combined in a weighted fashion into a single test statistic; imputation uncertainty was taken into account into Z-score and weight calculation using empirical variance calculated from allele dosage. For the original CeD GWAS scan, best guess imputed genotype frequency data was obtained, and association P-values were calculated using chi-square tests (1 df) of SNP allele counts.

The initial meta-analysis was performed using the statistical program R (http://www.r-project.org/). For both the CD and the CeD dataset the p-values signifying the evidence for association were converted to directional Z-scores, and an overall Z-score and two-tailed p-value for the average of the individuals was subsequently calculated. Given the fact that some controls were shared between one component of the CD meta-analysis and the CeD scan, we expect a correlation of 0.187 between CD and CeD Z-scores. We took this correlation into account in the variance term of the overall Z-score [24].

Unweighed Z-scores were used when combining the data from CD and CeD in the initial meta-analysis, since the CD cohort was
substantially larger than the CeD cohort and weighing would lead to an overrepresentation of the CD signal in the meta-analysis.

A locus was selected for replication when SNPs met the following criteria: a p-value for the locus of $<1 \times 10^{-5}$ in the meta-analysis, in combination with a p-value of $<1 \times 10^{-2}$ in the CeD dataset and a p-value of $<1 \times 10^{-3}$ in the CD dataset. Different thresholds for CD and CeD for inclusion in the replication phase were used to reflect the difference in power between the scans for the two phenotypes. For each of the loci that met these criteria, the most strongly associated SNP was analyzed in the CD and CeD replication cohorts.

In order to evaluate the expected number of SNPs that would pass our thresholds (p-value $<1 \times 10^{-2}$, $<1 \times 10^{-3}$ and $<1 \times 10^{-5}$ for CeD, CD and meta-analysis, respectively) by chance, we first evaluated the probability for a particular SNP to reach those thresholds under the null hypothesis of no association and the expected correlation between the two datasets. This probability can be calculated from the distribution of two correlated normal variables (correlation of 0.186), combined as described for the meta-analysis. We evaluated this probability to be approximately $6 \times 10^{-6}$. If the 468,378 SNPs tested in the scan were independent, we would then expect less than 3 ($468,378 \times 0.10 \times 10^{-6}$) independent SNPs to be selected by chance. Under a binomial model, we evaluated the probability that 9 or more independent SNPs passes our thresholds to be lower than 0.0025. Those are obviously upper bounds, as we know correlation exists among the SNPs tested.

**Replication phase**

For replication in CD, SNPs selected for testing were designed into multiplex assays, and genotyped using primer extension chemistry and mass spectrometric analysis (iPLEX assay, Sequenom, San Diego, California, USA) on the Sequenom MassArray. This was performed at the Laboratory for Genetics and Genomic Medicine of Inflammation (www.inflammgen.org) of the Universite de Montreal. Quality control was performed, excluding samples showing $>10\%$ missing data, as well as SNPs with $>10\%$ missing data or significantly out of Hardy-Weinberg equilibrium (p-value <0.001). The overall genotyping call rate in the CD replication dataset following quality control analyses was $>99\%$. The CD replication datasets from the two groups (Dutch and Italian) were combined and analyzed using a weighted and directional Z-score approach.

For replication in CeD, genotype frequencies and association data for five replication SNPs were obtained from genome-wide genotyping datasets on Illumina Human 670Quad or 610Quad Genotyping BeadChips (Illumina, Inc., San Diego, CA, USA). Each GWAS dataset was analyzed using PLINK 1.05 and association p-values were calculated using chi-square tests (1 df) of SNP allele counts [25]. Two of the replication SNPs were not included on the Illumina Human 670Quad or 610Quad Genotyping BeadChips. For these SNPs best guess genotype frequency data was obtained by imputation as described above, and association p-values were calculated using chi-square tests (1 df) of SNP allele counts. The CeD replication datasets from the three groups (UK, the Netherlands and Italy) were combined and analyzed using a weighted and directional Z-score approach.

Since selection of specific SNPs for replication was based on their association p-values in the combined CD-CeD dataset, a significant threshold for replication was set at a Bonferroni corrected p-value of 0.05 for 7 independent tests (p-value more significant than 0.0071) in the combined CD-CeD replication dataset. As for the initial meta-analysis, the data from the replication in the CD and CeD cohorts were combined through an unweighed Z-score approach. In addition, for a SNP to be replicated, both effect and direction of association trend needed to match between scan and replication within each disease.

For each SNP showing positive replication, an overall disease-specific association p-value, combining the scan and replication data, was also calculated using a weighted meta-analysis approach. Finally, an overall CD-CeD meta-analysis of the scan and replication phases of this study was obtained, by combining these within-CD and within-CeD datasets in an unweighed meta-analysis. Given the fact that some controls were shared between the within-CD and the within-CeD, we expect a correlation of 0.149 between CD and CeD Z-scores. As for the initial scan, we took this correlation into account in the variance term of the overall Z-score as per Lin and colleagues [24].

**Supporting information**

**Figure S1** Q-Q plot of meta-analysis scan. A meta-analysis scan of 471,504 SNPs from genomewide datasets of CD and CeD was performed using a directional non-weighed Z-score method (as explained in the methods section). The Q-Q plot was generated from the p-values for single-SNP Z scores. Given the strength of association signal for the MHC region (chr6:22,700,000-35,000,000) in CeD, this region overwhelmed the Q-Q plot and was therefore removed from the dataset for purpose of clarity; removing the MHC region had little impact on the observed inflation. Found at: doi:10.1371/journal.pgen.1001283.s001 (0.06 MB DOC)

**Figure S2** Manhattan plot of meta-analysis scan. A meta-analysis scan of 471,504 SNPs from genomewide datasets of CD and CeD was performed using a directional non-weighed Z-score method (as explained in the methods section). The Manhattan plot was generated from the p-values for single-SNP Z scores. Given the strength of association signal for the MHC region (chr6:22,700,000-35,000,000) in CeD, this region overwhelmed the Manhattan plot and was therefore removed from the dataset for purpose of clarity. Found at: doi:10.1371/journal.pgen.1001283.s002 (0.10 MB DOC)

**Table S1** Subjects included in study. Found at: doi:10.1371/journal.pgen.1001283.s003 (0.14 MB DOC)

**Table S2** Complete list of associated markers from meta-analysis. Found at: doi:10.1371/journal.pgen.1001283.s004 (0.01 MB XLSX)

**Acknowledgments**

The authors would like to acknowledge the use of the published results from the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC) meta-analysis of 3,230 CD cases and 4,829 healthy controls taken from three independent CD GWA (results available at http://www.broadinstitute.org/~jcharret/ibd-meta/). We acknowledge use of DNA from the British 1958 Birth Cohort collection. We thank all clinicians and Coeliac UK for assistance with direct recruitment of celiac disease individuals. We thank C. J. J. Mulder, M. L. Mearin, W. H. M. Verbeck, G. J. Tack, V. M. Wolters, R. H. J. Houwen for collection of Dutch CeD samples. We thank A. Andriulli, F. Bossa, D. Scimeca, and A. Latino for collection of Italian CD samples. We thank P. Deloukas, R. Gwiliam, and the Wellcome Trust Sanger Institute for UK control genotyping. We thank K. Hunt, V. Mistry, and G. Heap for sample preparation; A. Curtotti and C. Mein for assistance with UK case genotyping. This study makes use of data generated by the Wellcome Trust Case-Control Consortium 2. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. We thank all the individuals who participated in the study and J. Senior for critically reading the manuscript.
Author Contributions
Conceived and designed the experiments: EAMF PG MJ D CW JDR. Performed the experiments: CB PCD CL DAHV. Analyzed the data: EAMF PG TG GB CB GT PCD CL DAHV MJD CW JDR. Contributed reagents/materials/analysis tools: PCFS DWH DB OP VA DAHV RKW CW JDR. Wrote the paper: EAMF PG TG GB RKW MJD CW JDR.

References